Nurix Therapeutics, Inc. (NASDAQ:NRIX) has delivered a 63.93% return since Bond.az's Fair Value models identified the biotech stock as significantly undervalued in February 2024.
The analysis showed the stock was trading 49% below its intrinsic value at $9.87, and shares reached $16.18 by May 2026.
Fair Value analysis helps investors identify better entry and exit points.
Nurix operates with innovative protein regulation technology. The company reported revenue of $76.99 million, EBITDA of -$148.93 million, and EPS of -$2.65.
Strengths include high liquidity (current ratio 6.82) and strategic collaborations with Sanofi.
Recent developments: Phase 2 study for bexobrutideg and Sanofi extending its license option for the STAT6 program.
Current Fair Value at $17.02 suggests modest upside.
